VivoSim Labs Launches AI Tool to Predict Drug-Induced Diarrhea Without Animal Testing

Key Takeaways

• VivoSim Labs released an AI tool that predicts drug-induced diarrhea using human intestinal models instead of animal testing
• The platform leverages NAMkind™ technology and 3D assay results to improve drug safety predictions during preclinical development
• This advancement could accelerate drug development timelines while reducing costs and improving patient safety predictions

---

SAN DIEGO - VivoSim Labs, Inc. (Nasdaq: VIVS) announced April 28, 2026, the launch of an artificial intelligence prediction tool that accurately forecasts whether drug compounds will cause diarrhea in patients, using human intestinal models rather than animal testing.

Revolutionary Approach to Drug Safety Testing

The new platform utilizes VivoSim’s proprietary NAMkind™ intestinal models combined with machine learning algorithms trained on high-quality, real-world 3D New Approach Methodologies (NAM) assay results. This represents a significant advancement in preclinical safety testing, offering pharmaceutical companies a more accurate and ethical alternative to traditional animal-based studies.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Industry Implications

Gastrointestinal side effects, particularly diarrhea, represent one of the most common reasons for drug discontinuation and clinical trial failures. By providing early, accurate predictions of these adverse effects, VivoSim’s platform could help pharmaceutical companies:

• Reduce late-stage clinical trial failures
• Lower drug development costs
• Accelerate time-to-market for safer medications
• Eliminate ethical concerns associated with animal testing

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Technology Behind the Innovation

The AI model processes data from VivoSim’s human intestinal tissue models, which more accurately replicate human physiological responses compared to animal models. The platform analyzes compound interactions with human intestinal cells, providing pharmaceutical developers with predictive insights during the preclinical phase.

This launch positions VivoSim at the forefront of the growing New Approach Methodologies market, which is increasingly favored by regulatory agencies worldwide as they move toward reducing animal testing requirements.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Future Applications

While initially focused on diarrhea prediction, VivoSim’s platform technology could potentially expand to predict other gastrointestinal toxicities and adverse drug reactions, further revolutionizing preclinical safety assessment across the pharmaceutical industry.

---

Frequently Asked Questions

How accurate is VivoSim’s AI prediction tool compared to animal testing?

VivoSim’s platform uses human intestinal models, which typically provide more accurate predictions for human responses than animal models, though specific accuracy metrics weren’t disclosed in the announcement.

When will pharmaceutical companies be able to use this technology?

The AI prediction tool is now available to pharmaceutical companies for preclinical safety testing, according to VivoSim’s April 28, 2026 announcement.

What makes this different from existing drug safety testing methods?

Unlike traditional animal testing, VivoSim’s platform uses human intestinal tissue models combined with AI, providing more relevant human-specific predictions while eliminating ethical concerns about animal testing.

Related coverage

• MFN Drug Pricing Reshapes International Life Sciences Licensing Deals
• India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma
• CHMP May 2026 Output: A New Era in Drug Approvals